## OSCR: Oscar Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($13.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Oscar Health (OSCR): Evaluating Valuation After Policy Proposal Sparks Investor Optimism**
- Source: Sahm | 20251201T044314 | Neutral | Relevance: 99%
- Oscar Health (OSCR) shares surged after news of a potential two-year extension of Obamacare subsidies and expanded eligibility, sparking investor optimism despite the company's valuation being deemed "Overvalued" by analysts at $12.88. While the stock's one-year return is modest, its three-year return shows significant growth. The article also notes Oscar Health's low price-to-sales ratio compared to industry peers, suggesting potential for upside if market sentiment shifts.

**2. Why Oscar Health (OSCR) Is Up 33.3% After Analysts Highlight Resilience Amid ACA Subsidy Uncertainty**
- Source: Sahm | 20251201T044314 | Bullish | Relevance: 97%
-  Oscar Health (OSCR) saw a significant stock boost after analysts at Piper Sandler upgraded its rating, citing the company's resilience in gaining market share and improving profitability despite potential ACA subsidy uncertainties. The prospect of extended Affordable Care Act subsidies is highlighted as a key factor that could provide stability and consistent membership for Oscar Health, influencing its investment narrative positively. While Oscar Health shows growth in revenue and membership, profitability remains a challenge due to high operating costs.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | Piper Sandler | $25 | $13 | +92% |
| 2025-11-13 | Wells Fargo | $11 | $14 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | Piper Sandler | up | Overweight |
| 2025-11-13 | Wells Fargo | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.09M) |
| Sells | 7 ($1.04M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+2.1%)
- Blackrock Inc.: 7.1% (+2.7%)
- T. Rowe Price Invest: 3.6% (-34.3%)
- Thrive Capital Manag: 2.8% (0.0%)
- American Century Com: 2.3% (+89.0%)

### Key Risks

1. High beta (1.88) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.6%): bears positioning against stock.
3. Near-term weakness: 8.2% below SMA50 despite long-term uptrend.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.5B |
| Beta | 1.88 |
| 52W Range | $11.20 - $23.80 |
| Short Interest | 13.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 stable at 5.0% (minimal 5-day change). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 (-3.7%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.0% shows strong absolute momentum above own 20MA. Outperforming sector by 3.7pp, stock-specific strength. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.03% (CS: 89) | Strong |
| RSI_14 | 50.2 | Neutral |
| MACD Histogram | 0.47 | Bullish |
| vs SMA20 | 1.060x | Above |
| vs SMA50 | 0.918x | Below |
| vs SMA200 | 1.040x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $16.65
- **Stop Loss:** $13.97 (16.1% risk)
- **Target:** $19.33 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 279
- **Position Value:** $4,645.35
- **Portfolio %:** 4.65%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-03 (Est: $-0.92)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.58 | $-0.53 | +8.6% |
| 2025Q2 | $-0.84 | $-0.89 | -6.5% |
| 2025Q1 | $0.81 | $0.92 | +13.9% |
| 2024Q4 | $-0.58 | $-0.62 | -6.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*